Eliminating antibiotic prophylaxis for intravitreal injections: A consecutive series of 18,839 injections by a single surgeon

Retina

Volumn 35, Issue 4, 2015, Pages 783-788

  Bhavsar, Abdhish R ^a   Sandler, Danielle R ^b  

^a Retina Center of Minnesota   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

antibiotics; bevacizumab; complications; eliminating; endophthalmitis; intravitreal injection; omitting; ranibizumab; triamcinolone; vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; DEXAMETHASONE SODIUM PHOSPHATE; GANCICLOVIR; PEGAPTANIB; POVIDONE IODINE; PREDNISOLONE ACETATE; PROXYMETACAINE; RANIBIZUMAB; TETRACAINE; TRIAMCINOLONE ACETONIDE; ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT; EYE DROPS; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ANTERIOR EYE CHAMBER; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CILIARY DISK; CYTOMEGALOVIRUS RETINITIS; DIABETIC MACULAR EDEMA; ENDOPHTHALMITIS; EPIRETINAL MEMBRANE; FEMALE; GLAUCOMA; GLOVE; HUMAN; INJECTION; MAJOR CLINICAL STUDY; MALE; OPHTHALMIC SPECULUM; RETINA DETACHMENT; RETINA MACULA CYSTOID EDEMA; RETROSPECTIVE STUDY; SECONDARY GLAUCOMA; SURGEON; TOPICAL TREATMENT; UVEITIS; VISUAL ACUITY; VITRECTOMY; CLINICAL PRACTICE; INCIDENCE; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PROCEDURES; RETINAL DISEASES; TOPICAL DRUG ADMINISTRATION; UNITED STATES; VERY ELDERLY;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ENDOPHTHALMITIS; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MINNESOTA; OPHTHALMIC SOLUTIONS; PHYSICIAN'S PRACTICE PATTERNS; RETINAL DISEASES; RETROSPECTIVE STUDIES;

EID: 84926189446     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000392     Document Type: Article

References (31)

1. Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology 1991;98:1769-1775.
2. Isenberg SJ, Apt L, Yoshimori R, Khwarg S. Chemical preparation of the eye in ophthalmic surgery. IV. Comparison of povidone-iodine on the conjunctiva with a prophylactic antibiotic. Arch Ophthalmol 1985;103:1340-1342.
3. Apt L, Isenberg SJ, Yoshimori R, et al. The effect of povidoneiodine solution applied at the conclusion of ophthalmic surgery. Am J Ophthalmol 1995;119:701-705.
4. Moss JM, Sanislo SR, Ta CN. A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections. Ophthalmology 2009;116: 1498-1501.
5. Hyon JY, Eser I, O'Brien TP. Kill rates of preserved and preservative-free topical 8-methoxy fluoroquinolones against various strains of Staphylococcus. J Cataract Refract Surg 2009;35:1609-1613.
6. Callegan MC, Novosad BD, Ramadan RT, et al. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones. Adv Ther 2009;26:447-454.
7. Puustjarvi T, Terasvirta M, Nurmenniemi P, et al. Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye. Graefes Arch Clin Exp Ophthalmol 2006;244:1633-1637.
8. Sakamoto H, Sakamoto M, Hata Y, et al. Aqueous and vitreous penetration of levofloxacin after topical and/or oral administration. Eur J Ophthalmol 2007;17:372-376.
9. Yalvac IS, Basci NE, Bozkurt A, Duman S. Penetration of topically applied ciprofloxacin and ofloxacin into the aqueous humor and vitreous. J Cataract Refract Surg 2003;29: 487-491.
10. Yin VT, Weisbrod DJ, Eng KT, et al. Antibiotic resistance of ocular surface flora with repeated use of a topical antibiotic after intravitreal injection. JAMA Ophthalmol 2013;131: 456-461.
11. Dave SD, Toma HS, Kim SJ. Ophthalmic antibiotic use and multidrug-resistant Staphylococcus epidermidis: a controlled, longitudinal study. Ophthalmology 2011;118:2035-2040.
12. Kim SJ, Toma HS. Antimicrobial resistance and ophthalmic antibiotics: 1-year results of a longitudinal controlled study of patients undergoing intravitreal injections. Arch Ophthalmol 2011;129:1180-1188.
13. Mason JO III, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008;28:564-567.
14. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008;145:879-882.
15. Scott IU, Flynn HW Jr. Reducing the risk of endophthalmitis following intravitreal injections. Retina 2007;27:10-12.
16. Meyer CH, Mennel S, Eter N. Incidence of endophthalmitis after intravitreal Avastin injection with and without postoperative topical antibiotic application [in German]. Ophthalmologe 2007;104:952-957.
17. Bhavsar AR, Googe JM Jr, Stockdale CR, et al. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol 2009;127:1581-1583.
18. Bhavsar AR, Stockdale CR, Ferris FL III, et al. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. Arch Ophthalmol 2012;130:809-810.
19. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
20. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
21. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007;144:850-857.
22. Bhavsar AR. Avoiding endophthalmitis following intravitreal injections. Retinal Physician 2013. Available at: http://www. retinalphysician.com/articleviewer.aspx?articleID=108234. Accessed April 3, 2014.
23. Englander M, Chen TC, Paschalis EI, et al. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates. Br J Ophthalmol 2013;97:460-465.
24. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, et al. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center. Retina 2011;31:662-668.
25. Falavarjani KG, Modarres M, Hashemi M, et al. Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinical center. Retina 2013;33:971-974.
26. Cheung CS, Wong AW, Lui A, et al. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology 2012;119:1609-1614.
27. Bhatt SS, Stepien KE, Joshi K. Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate. Retina 2011;31:2032-2036.
28. Lyall DA, Tey A, Foot B, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye (Lond) 2012;26:1517-1526.
29. Bhavsar AR, Sandler DR, Gentile RC. Intravitreal injections, antibiotics and endophthalmitis. Eye (Lond) 2013;27:1426-1427.
30. Shimada H, Hattori T, Mori R, et al. Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask. Graefes Arch Clin Exp Ophthalmol 2013;251:1885-1890.
31. Brynskov T, Kemp H, Sørensen TL. No cases of endophthalmitis after 20,293 intravitreal injections in an operating room setting. Retina 2014;34:951-957.